Relmada Therapeutics to Transfer Listing to OTCQB

TL;DR

Nasdaq delisting incoming, moving to OTCQB Jan 27.

AI Summary

Relmada Therapeutics, Inc. received a notice on January 21, 2025, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Market. The company is transferring its listing from the Nasdaq Capital Market to the OTCQB Venture Market, effective January 27, 2025. This follows a prior notification from Nasdaq on January 17, 2025, regarding non-compliance with listing requirements.

Why It Matters

This delisting from Nasdaq and move to OTCQB signifies a significant downgrade in the company's market accessibility and potentially investor confidence, impacting its ability to raise capital and its stock's liquidity.

Risk Assessment

Risk Level: high — Delisting from a major exchange like Nasdaq to a less regulated over-the-counter market indicates severe financial distress or non-compliance, posing significant risk to investors.

Key Players & Entities

• Relmada Therapeutics, Inc. (company) — Registrant
• Nasdaq Capital Market (company) — Exchange from which listing is being transferred
• OTCQB Venture Market (company) — Exchange to which listing is being transferred
• January 21, 2025 (date) — Date of notice of delisting
• January 27, 2025 (date) — Effective date of transfer to OTCQB
• January 17, 2025 (date) — Date of prior Nasdaq notification

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The Nasdaq
• $1 — did not maintain a minimum bid price of $1 per share. Nasdaq stated in its letter

Filing Documents

• ea0228747-8k_relmada.htm (8-K) — 30KB
• 0001213900-25-006727.txt ( ) — 200KB
• rlmd-20250121.xsd (EX-101.SCH) — 3KB
• rlmd-20250121_lab.xml (EX-101.LAB) — 33KB
• rlmd-20250121_pre.xml (EX-101.PRE) — 22KB
• ea0228747-8k_relmada_htm.xml (XML) — 4KB

01. Notice of Delisting or Failure to Satisfy a Continued

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 21, 2025, Relmada Therapeutics, Inc. (the "Company") received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") notifying the Company that, for the 30 consecutive business days ended January 17, 2025, the Company's security did not maintain a minimum bid price of $1 per share. Nasdaq stated in its letter that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days from the date of the notice ("Compliance Period"), and that it may regain compliance if the closing bid of the Company's security is at least $1 for a minimum of ten consecutive business days during the Compliance Period, which will end on July 21, 2025. If the Company chooses to implement a reverse stock split, it must complete the split no later than ten business days prior to the expiration of the Compliance Period, in order to regain compliance. The notification from Nasdaq does not impact the listing of the Company's common stock at this time. The Company intends to actively monitor the Company's bid price during the Compliance Period and intends to take all reasonable measures available to regain compliance with the requirements for continued listing on the Nasdaq Global Market. If the Company does not regain compliance with the continued listing requirements for the minimum bid price by the end of the Compliance Period, the Nasdaq Staff will provide the Company with written notification that the Company's common stock is subject to delisting from the Nasdaq Global Market. Alternatively, Nasdaq Marketplace Rules may permit the Company to transfer the Company's common stock to the Nasdaq Capital Market prior to the Compliance Date, if the Company's common stock satisfies the criteria for continued listing on such market. While the Company plans to make diligent efforts

Forward-Looking Statements

Forward-Looking Statements Certain statements in this Current Report on Form 8-K (the "Current Report") are "forward-looking statements" that are subject to substantial risks and uncertainties. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this Current Report may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words and include, without limitation, statements regarding the Company's ability to regain compliance with the minimum bid price rule for the Nasdaq Global Market; the Company's intent to monitor its bid price and intention to take all reasonable measures available to the Company to regain compliance with requirements for continued listing on the Nasdaq Global Market; or the Company's success in changing the listing to the Nasdaq Capital Market.

Forward-looking statements are based on the

Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the Company's ability to regain compliance with the minimum bid price; and the other important factors outlined under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"), the latest Form 10-Q filed with the, as such factors may be updated from time to time in its other filings with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this Current Report on Form 8-K to reflect changes since the date of this Current Report on Form 8-K, except as may be required by law. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 27, 2025 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR